This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / ATyr Pharma Class Action Lawsuit
Business class action

ATyr Pharma Class Action Lawsuit

Analysis based on 10 articles · First reported Oct 15, 2025 · Last updated Nov 18, 2025

Sentiment
-20
Attention
2
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against ATyr Pharma, Inc. could negatively impact its stock price and investor confidence due to allegations of misleading statements regarding its drug Efzofitimod. Investors who purchased ATyr Pharma common stock during the Class Period may be entitled to compensation, potentially leading to financial liabilities for ATyr Pharma.

Biotechnology Legal Services
Event Summary

Rosen Law Firm has filed a class action lawsuit against ATyr Pharma, Inc. on behalf of investors who purchased common stock between January 16, 2025, and September 12, 2025. The lawsuit alleges that ATyr Pharma, Inc. made false and misleading statements and concealed material adverse facts concerning the efficacy of its drug Efzofitimod, specifically its ability to allow patients to completely taper steroid usage. Investors are encouraged by Rosen Law Firm to join the class action by the December 8, 2025, lead plaintiff deadline. The firm, represented by attorneys Philip Kim and Lawrence Rosen, aims to recover damages for investors who suffered losses when the true details about Efzofitimod's efficacy became known.

Entities Involved
stock
ATyr Pharma
ATyr Pharma is the defendant in a class action lawsuit, accused of making false and misleading statements regarding the efficacy of its drug Efzofitimod, which could lead to financial damages for the company.
Importance 100.0 Sentiment -40.0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where aTyr Pharma, Inc. common stock is traded, making it relevant for investors who purchased shares during the Class Period.
Importance 10.0 Sentiment 0.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
Relationships
Nasdaq-100 related ↔ Rosen Law Firm
Nasdaq-100 related ↔ Philip Kim
Nasdaq-100 related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.